Heparin Induced Thrombocytopenia (HIT)
Educational only: videos on MedicalVideos.com are for general information and are not medical advice. Always consult your own doctor about your health.
All forms of heparin (including low-molecular-weight heparin such as enoxaparin) must be stopped immediately in patients with suspected heparin-induced thrombocytopenia (HIT) while awaiting diagnostic confirmation. Patients with HIT remain at high risk of thrombosis even after discontinuation of heparin. Therefore, an alternate, rapidly acting, non-heparin anticoagulant such as direct thrombin inhibitor (eg, argatroban, bivalirudin) must be started immediately.
This video in 30 seconds
This video covers heparin-induced thrombocytopenia (HIT). It explains that all forms of heparin must be stopped when HIT is suspected while diagnostic confirmation is awaited, that patients remain at high risk of thrombosis even after heparin is stopped, and that an alternate, rapidly acting, non-heparin anticoagulant is started instead.
Key points
- Covers stopping all forms of heparin, including low-molecular-weight heparin, when HIT is suspected
- Explains that thrombosis risk remains high after heparin discontinuation
- Covers use of an alternate non-heparin anticoagulant such as a direct thrombin inhibitor
Video Overview
This video presents “Heparin Induced Thrombocytopenia (HIT)” — All forms of heparin (including low-molecular-weight heparin such as enoxaparin) must be stopped immediately in patients with suspected heparin-induced thrombocytopenia (HIT) while awaiting diagnostic confirmation. Patients with HIT. Whether you are preparing for a procedure, studying the technique, or learning how a condition is assessed, the recording shows the process as it is performed in practice.
From our Pharmacology collection: How drugs work — mechanisms, side effects and prescribing basics explained clearly for medical and pharmacy students. Browse all Pharmacology videos →
Educational content only — not a substitute for professional medical advice.
SORT BY-
Top Comments
-
Latest comments